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Background: As therapeutic options evolve for advanced heart failure, the appro-
priate role for cardiac transplantation will require survival analyses that reflect
changing trends in causes of death and patient and institutional risk profiles. Results
from multi-institutional studies could be used to monitor progress in individual centers.
Methods: Between 1990 and 1999, 7290 patients undergoing cardiac transplantation
in 42 institutions entered a formal outcomes study. Changing survival, causes of
death, and patient risk profiles were analyzed. Multivariable risk-factor equations
were applied to a single institution (300 primary heart transplants) to examine
differences in risk-adjusted expected versus observed actuarial outcomes over time.
Results: Overall survival in the 42 institutions improved during the decade (P 
.02). One- and 3-year cardiac transplant research database survival was as follows:
era 1 (1990-1992), 84% and 76%, respectively; era 2 (1993-1995), 85% and 79%,
respectively; and era 3 (1996-1999), 85% and 79%, respectively. Causes of death
changed over time. Pretransplantation risk profiles increased over time (P  .0001),
with increases in reoperations, devices, diabetes, severely ill recipients, pulmonary
vascular resistance, sensitization, ischemic times, donor age, and donor inotropic
support. Three-year actuarial survival in a single institution was 3% less than
risk-adjusted predicted survival in era 1, 1% higher than predicted in era 2, and 7%
higher than predicted in era 3.
Conclusions: Survival after cardiac transplantation is gradually improving, despite
increasing risk profiles. Further improvement requires periodic re-evaluation of risk
profiles and causes of death to target areas of surveillance, therapy, and research. By
using these methods, progress at individual institutions can be assessed in a
time-related, risk-adjusted manner that also reflects changing institutional experi-
ence, expertise, or both.
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During the past 35 years of experience withhuman heart transplantation, many impor-tant advances have occurred that cur-rently allow nearly routine early survivaland a high probability of intermediate-term survival, yet still disappointing late
survival after cardiac transplantation. The advances in do-
nor heart preservation, new and evolving immunosuppres-
sive modalities and strategies, and emerging potential ther-
apies for chronic rejection (allograft vasculopathy) have
drastically changed the expectations of patients undergoing
heart transplantation and transplant physicians since the
initial decade of experience in the late 1960s and 1970s.
Despite substantial advances, patients undergoing trans-
plantation continue to face the potential of death from 5
major causes: early graft failure, allograft rejection, infec-
tion, allograft vasculopathy, and malignancy.1
Because of the ongoing donor shortages, the experience
and level of expertise at individual institutions is variable
and often limited by a small number of transplant proce-
dures. Multi-institutional studies have emerged as an im-
portant method of understanding truths regarding outcomes
in clinical cardiac transplantation through meaningful risk-
factor analyses of a large patient population.
This 10-year multi-institutional analysis was undertaken
to examine changes in causes of death and patient risk profiles
over the most recent decade of cardiac transplantation.
Materials and Methods
Study Population
The cardiac transplant research database (CTRD) is a multi-insti-
tutional, prospective, event-driven database that began in January
1990. The focus of this database has been the identification of
time-related frequency of and risk factors for major morbid events
and mortality (both general and cause specific) after cardiac trans-
plantation at Medicare-approved facilities in the United States. The
study population includes 7290 patients undergoing cardiac trans-
plantation at 42 institutions over a 10-year period (Appendix 1).
All patients at participating institutions are included in the analy-
sis, but some institutions participated in the database for a portion
of the decade. Follow-up as of January 1, 2000, was complete on
93% of study patients.
Specific data are collected at the time of transplantation, at the
time of occurrence of morbid or fatal events, and on a yearly basis.
Data compiled included extensive donor and recipient demo-
graphic variables and data regarding rejection, infection, retrans-
plantation, malignancy, and allograft vasculopathy.
Data entry, checking, and maintenance are based at the CTRD
Coordinating Center at the University of Alabama at Birmingham
(UAB). The primary end point of this study was death from all
causes. Each study center independently verified the cause of
death, which was subsequently also verified by the coordination
and analysis center at UAB. In cases in which multiple causes
contributed to the final fatal outcome, a primary cause of death was
assigned. The primary cause of death (and not contributing causes)
was analyzed in this study.
Data Analysis
Standard time-related actuarial and parametric survival analyses in
the hazard function domain were used to examine freedom from
overall death and cause-specific mortality after transplantation.2
The methods of competing outcomes analysis3 were used to ex-
amine the contribution from differing causes of death over time,
both in relationship to the time after and the year of transplantation.
Potential risk factors for death were examined by using multivariable
hazard function analysis (Appendix 2). Risk factors were retained in
the model if the P value was less than .05. The mortality observed in
a specific institution (observed survival) was compared with the
overall group performance by applying the risk-factor model to the
specific patients within the single institution, and the expected sur-
vival at a specific time after transplantation was further adjusted by
the era of transplantation within the decade of study.
Results
Survival
Among the 7290 patients undergoing cardiac transplanta-
tion between 1990 and 1999, 1-year survival was 85%,
Figure 1. Actuarial and parametric survival after transplantation,
including all patients during this 10-year experience. The lower
curve represents the hazard function for death, with the units on
the right-sided vertical axis.
TABLE 1. CTRD: 1990 to 2000 —Time distributions of causes
of death
Primary cause of death
Years after transplantation
<1 y
(n [%] of 1076)
1-4 y
(n [%] of 488)
5-10 y
(n [%] of 300)
Early graft failure 217 (20) 0 (0) 0 (0)
Rejection 166 (15) 59 (12) 14 (5)
Infection 268 (25) 51 (10) 25 (8)
Nonspecific graft failure 57 (5) 38 (8) 7 (2)
Sudden 36 (3) 49 (10) 18 (6)
Neurologic 48 (4) 16 (3) 13 (4)
Malignancy 27 (3) 78 (16) 87 (29)
CAD 47 (4) 93 (19) 68 (23)
Other 210 (20) 104 (21) 68 (23)
Total 1076 (100) 488 (100) 300 (100)
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3-year survival was 78%, and 7-year survival was 66%
(Figure 1). The hazard function for death was highest during
the first 3 months and rapidly decreased thereafter, merging
with a constant hazard function by 2 years. A late increasing
hazard function was identified, with its effect becoming
apparent after 6 years.
Causes of Death
The causes of death during this decade of experience ac-
cording to the elapsed time after transplantation are listed in
Table 1. During the first year, the major causes of death
were early graft failure, infection, and rejection. Between 1
and 4 years, allograft vasculopathy was the major cause of
death, followed by malignancy and rejection. After the
fourth year, malignancy emerged as the leading cause of
death. This evolution of likely causes of death related to
evolving time after transplantation is reflected in the hazard
functions for specific causes of death (Figure 2).
There was also a change in the proportion of patients
who died from specific causes over the course of the study.
The percentage of patients dying from early graft failure,
malignancy, and infection within 3 years remained rela-
tively constant over the decade. However, there was a
progressive reduction in the likelihood of death from rejec-
tion and allograft vasculopathy during the first 3 years for
patients transplanted during the latter part of the decade
compared with those transplanted during earlier years (Fig-
ure 3).
Risk Factors for Mortality
The recipient and donor risk factors that were independent
depictors of death in the early, constant, and late phases
after cardiac transplantation are listed in Table 2. An earlier
date of transplantation was an important additional risk
factor for mortality in the constant phase, with a relative risk
of 1.9 comparing 1992 with 1999.
Changing Risk Profiles Over Time
To evaluate the possibility that patients were either at lower
or higher risk during the later period of this experience, the
severity of the risk factors listed in Table 2 were profiled for
3 eras: 1990 through 1992 (1754 patients), 1993 through
1995 (2220 patients), and 1996 through 1999 (3316 pa-
tients) (Table 3). Note that patients transplanted were pro-
gressively more ill, as reflected by an increasing number of
ventricular assist devices prior to transplantation and a
greater proportion of status I patients at transplantation.
The transplant operation was more often complicated
during the later years, as reflected by more previous
sternotomies and more ventricular assist devices at trans-
plantation. The number of sensitized patients also grad-
Figure 2. A, Hazard functions for the specific causes of death during the first 4 months after cardiac transplantation.
B, Hazard functions for specific causes of death after the first year after cardiac transplantation. CAD, Coronary
artery disease.
Figure 3. Proportion of patients who died from specific causes
within the first 3 years after transplantation depicted by the year
of transplantation (indicated along the horizontal axis). The pro-
portion of patients dying from malignancy, early graft failure, and
infection remained constant over the decade, whereas the pro-
portion of patients dying from allograft vasculopathy and rejec-
tion within 3 years decreased during the decade experience.
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ually increased. Donor age increased, ischemic time
lengthened, and the percentage of donors receiving pres-
sors increased during the decade.
Risk-adjusted Survival
The actuarial survival during each of these 3 time periods is
depicted in Figure 4. Although the earlier period (1990-
TABLE 2. Risk factors for death from any cause (CTRD: 1990-1999, n  7290)
Risk factor
Early phase Constant phase Late phase
Relative
risk P value
Relative
risk P value
Relative
risk P value
Recipient
Older age* 1.13 .008 1.41 .008
Younger age† 1.94 .0002
Black 2.02 .001
Obese recipient‡ 2.35 .005
Cachectic recipient§ 2.5 .01
Congenital cause 1.89 .002
Noncongenital cause 3.76 .03
Insulin-dependent diabetes 1.66 .0004
Pulmonary disease 1.35 .03
Peripheral vascular disease 11.3 .03
Herpes negative 1.29 .03
Cigarette use within 6 mo 1.49 .0005
Cocaine use 3 .0005
Lower creatinine clearance at listing 1.28 .0006
Higher serum creatinine at transplantation 1.43 .0001 1.23 .01
PAS-PCWP¶ 1.4 .0005
Mean RAP# 1.22 .01
PRA 10 1.71 .0001
Previous sternotomy 1.44 .0001
1 previous sternotomy 1.77 .03
Ventilator 2.18 .0001
IABP 1.36 .01
VAD, 14 d or less 1.86 .005
Days on VAD** 1.29 .04
Earlier date of transplantation†† 1.91 .0001
Donor
Older donor age§§ 1.24 .0001 1.23 .0001
Female 1.36 .0001
Male 1.23 .03
Abnormal echo 1.7 .01
Diabetes 2.06 .01
Longer ischemic time 1.7 .0001
Mismatch
Recipient BMI-donor BMI (smaller donor,
larger recipient)¶¶
1.49 .004
PAS, Pulmonary artery systolic pressure; PCWP, mean pulmonary capillary wedge pressure; RAP, right atrial pressure; PRA, panel reactive antibody; IABP,
intra-aortic balloon pump; VAD, ventricular assist device; BMI, body mass index.
*Relative risk compares age 50 years with age 60 years.
†Relative risk compares age 30 years with age 20 years.
‡Relative risk compares body mass index of 25 with body mass index of 30.
§Relative risk compares body mass index of 25 with body mass index of 15.
Relative risk compares creatinine clearance of 100 with creatinine clearance of 50.
¶Relative risk compares serum creatinine level of 1.0 with serum creatinine level of 2.0.
#Relative risk compares systolic pulmonary gradient of 15 with systemic pulmonary gradient of 40.
**Relative risk compares right atrial pressure of 5 with right atrial pressure of 20.
††Relative risk compares days on vascular assist device of 30 with days on vascular assist device of 180
‡‡Relative risk compares transplant year of 1999 with transplant year of 1992.
§§Relative risk compares donor age of 25 years with donor age of 40 years.
Relative risk compares ischemic time of 180 with ischemic time of 300.
¶¶Relative risk compares body mass index difference of 10 with body mass index difference of 20.
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1992) showed a significant reduction in survival compared
with that seen in later years, the magnitude of that dif-
ference was small. To further evaluate the adverse effect
of increasing risk profiles (Table 3) on the one hand and
the favorable effect of a later transplantation date (Table
2), a separate depiction was generated to indicate the
magnitude of these effects. By solving the multivariable
equations (Table 2) for the risk profile of patients and
donors in 1990 and setting the date of transplantation as
1990, a 3-year survival of 76% (Figure 5, upper straight
line) is projected over the decade, indicating the outcome
if the risk profile remained stable and no institutional
improvement occurred over time. The effect of a chang-
ing patient risk profile can be isolated and displayed by
leaving the date of transplantation variable constant and
calculating the risk-adjusted 3-year survival for the co-
hort of patients transplanted in each 6-month interval
(Figure 5, bottom jagged curve). The difference between
these curves at any time during the decade can be quan-
tified as the risk-profile effect compared with patients
transplanted in 1990.
The date of transplant as a separate risk factor revealed a
progressive improvement in survival with increasing year
of transplantation, likely indicating institutional or era
improvements. This institutional-era effect is depicted in
Figure 6. The lower curve once again reflects the 3-year
survival for patients transplanted in 1990, assuming no
effect of date of transplantation and no change in risk
factors over the decade. The upper line depicts the im-
provement in survival over the decade when the risk
profile is maintained at the 1990 level and only the date
of transplantation variable changes. The area between the
2 curves indicates the isolated institutional-era effect
(date of transplantation) on improved 3-year survival
over the decade of experience.
The overall effect of these 2 factors (increasing risk
profile and institutional-era effect) is depicted in Figure 7.
Note that these 2 effects act in opposite directions; namely,
the risk-profile effect (higher-risk patients later in decade)
acts to decrease expected survival, whereas the institutional-
era effect (improving outcome with later date of transplan-
tation) acts to increase survival. The interaction of these 2
factors produces a slight progressive increase in 3-year
survival over the course of the decade.
Application of Risk Profiles to Individual Institutions
The equations from the multivariable risk-factor analysis for
CTRD were applied to a single institution (UAB) to exam-
ine differences in expected versus observed survival as a
reflection of the date of transplantation (Figure 8). The 3
panels correspond to patients transplanted between 1990
and 1992, 1993 and 1995, and 1996 and 1999. Note that the
UAB observed survival was less than the expected value
(according to the CTRD risk-adjusted predictions) in 1990
through 1992 (Figure 8, A), and the observed and expected
survivals were nearly superimposed for the experience be-
tween 1993 and 1995 (Figure 8, B). During the most recent
5-year experience, the UAB survival exceeded the risk-
adjusted CTRD prediction (Figure 8, C).
This UAB institution-era effect is depicted in Figure 9 as
the shaded area between the expected and observed curves.
Thus in the early part of the decade, this single-institution
experience reflected worse risk-adjusted survival than ex-
pected by the CTRD equation (negative institutional-era
effect), but by the latter portion of the decade, the single-
Figure 4. Actuarial survival after cardiac transplantation stratified
by era of transplantation: 1990 through 1992, 1993 through 1995,
and 1996 through 1999.
Figure 5. Risk-profile effect during the decade of transplantation.
The upper solid curve indicates the 3-year survival for patients
undergoing transplantation with a risk profile present in 1990 and
with the variable “transplant date” set at 1990. The lower curve
maintains the same transplantation date (1990) but demonstrates
the effect of changing risk profile over the decade. The risk
profile for patients in each 6-month interval are used to calculate
the expected 3-year survival. Note that the effect of the changing
risk profile is such that higher-risk patients were undergoing
transplantation in later years of the experience.
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institution survival exceeded that predicted by the risk-
factor equations (positive institutional-era effect).
Discussion
Study Limitations
Despite the obvious power of more than 7000 patients
compromising the study group, the study is limited by the
disadvantages of multi-institutional databases. Although the
event-driven design of this database is unique and rigorous
in terms of follow-up and data checking, considerable in-
terinstitutional differences exist. For example, a specific
cause of death must be assigned by the investigators at each
institution. Because of the frequent interaction between
various morbid events contributing to a final fatal outcome,
differences might exist as to the exact cause of death in a
Figure 6. Institutional-era effect (date of transplantation effect).
The lower solid curve is the same as the upper solid curve in
Figure 5, indicating the date of transplantation as 1990 and a risk
profile for 1990. The upper curve assumes a constant risk profile
(1990 level) for patients operated on during the decade and
demonstrates the effect of increasing date of transplant. The
shaded area between the curves indicates the improvement in
3-year survival attributed to the institutional-era effect.
Figure 7. Combined risk profile and institutional-era effects. Fig-
ure 7 represents a composite of Figures 5 and 6, in which A is the
isolated risk-profile effect (increasing risk factors), B indicates
the isolated institutional-era effect, and C indicates the actuarial
3-year survival for patients transplanted in each 6-month interval
over the decade, taking into account both increasing risk factors
and the institutional-era effect. This results in a gradual increase
in 3-year survival over the decade of experience.
TABLE 3. CTRD
Year of transplantation
P value
1990-1992
(n  1754)
1993-1995
(n  2220)
1996-1999
(n  3316)
Recipient
Age (ys) 51.2 52.3 52.9 .0001
Diabetes 13.0% 15.0% 19.0% .0001
Pulmonary resistance (units  m2) 4.8 5.2 5.3 .0001
PRA 10 (best) 2.7% 5.1% 6.2% .0001
PRA 10 (worst) 3.4% 6.0% 8.6% .0001
Previous sternotomy 38.0% 41.0% 46.0% .0001
IABP at transplant 8.7% 7.3% 4.9% .0001
VAD at transplant 3.0% 8.0% 18.0% .0001
Status 1 at transplant 45.0% 59.0% 72.0% .0001
Donor
Age (y) 29.4 29.6 31.6 .0001
Age 40 y 21.0% 24.0% 30.0% .0001
Ischemic time (min) 159 171 176 .0001
Ischemic time 300 min 1.3% 2.4% 3.0% .002
White 83.0% 78.0% 85.0% .0001
Black 10.0% 12.0% 12.0% .08
On pressors 73.0% 83.0% 86.0% .0001
PRA, Panel-reactive antibody; IABP, intra-aortic balloon pump; VAD, ventricular assist device.
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given patient. For example, the assignment of rejection as
an event and cause of death was frequently, but not uni-
formly, associated with clear evidence on endomyocardial
biopsy or autopsy. Thus in the clinical practice of transplan-
tation and in this study, some uncertainty frequently exists
as to the diagnosis of allograft rejection in the setting of
circulatory compromise. Infection is a frequent complica-
tion of aggressive immunosuppression in the setting of
recurrent or severe rejection, further complicating the as-
signment of a primary cause of death in that setting. Other
confounding issues include the differentiation of early graft
failure from accelerated early rejection as a cause of death.
In any event-driven study of this magnitude, the possi-
bility always exists of underreporting of events by individ-
ual institutions. In this study, however, death is the single
end point that is most rigorously identified.
Causes of Death
It is of interest that allograft vasculopathy (transplant cor-
onary artery disease) and malignancy emerge as the leading
causes of death after the first several years after transplan-
tation. It has long been the perception of many transplant
physicians that allograft vasculopathy will be the major
factor that limits long-term survival. This study casts some
doubt on that assertion, at least in the current era of immu-
Figure 8. A, Actuarial survival (bottom curve) at UAB, 1990 through 1992. The upper curve represents the expected
survival for UAB on the basis of risk adjustment according to the CTRD 10-year multivariable analysis. B, The same
depiction as in A for the years 1993 through 1995. C, The same depiction as in A for the years 1996 through 1999.
Figure 9. The expected versus observed survival at UAB for the 3
time periods depicted in Figure 8. The shaded area between the
2 curves represents the changing differences between observed
and expected survival over time.
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nosuppression. A review of Figure 2, B, indicates that
although allograft vasculopathy provides the greatest hazard
for death in the intermediate term (2-4 years after transplan-
tation), malignancy emerges as the most likely cause of
death after about 5 years. The ongoing and increasing risk of
late fatal malignancy should be emphasized as longer-term
survival becomes routine. Elimination of posttransplant risk
factors for malignancy, such as continued smoking and
appropriate surveillance protocols, are an increasingly im-
portant component of long-term care of transplant recipi-
ents.
The changing proportion of patients dying from various
causes of death over the decade of this study provides
important insights regarding the state of progress of trans-
plantation therapy. Death from rejection and allograft vas-
culopathy (Figure 3) have decreased in frequency over the
decade. This likely reflects advances in immunosuppressive
modalities, both maintenance therapy and acute rejection
treatments. A survival benefit has been suggested with my-
cophenolate compared with azathioprine,4 and many insti-
tutions currently routinely use mycophenolate as part of
maintenance immunosuppression. Photopheresis5,6 has pro-
vided more successful treatment of recurrent rejection in the
recent era, and plasmapheresis has evolved over the past
decade into a near-routine component of therapy for rejec-
tion with hemodynamic compromise, a frequently lethal
event.7
The reasons for decreasing mortality from allograft vas-
culopathy are unclear but might relate to more effective
antirejection therapy, given the known relationship between
frequent rejection and subsequent allograft vasculopathy.8,9
A greater emphasis on treatment of hyperlipidemia and
other risk factors for generalized atherosclerosis might be
having some (as yet unproven) beneficial effect.
The finding of the absence of decreasing early mortality
from early graft failure, infection, and malignancy is disap-
pointing and indicates that considerable work remains in the
areas of improved donor heart preservation and early detec-
tion and treatment of malignancies and infections after
transplantation.
Analysis of Survival
This study emphasizes that a simple actuarial depiction of
survival in differing eras (Figure 4) often provides incom-
plete information. Proper multivariable risk-factor analyses
play a critical role in identifying risk factors for adverse
outcomes. This study further underscores the importance of
examining changing risk profiles (the risk-profile effect) in
comparing one era to another. Indeed, the findings in this
study support the long-held clinical impression that patients
undergoing transplantation have become progressively
sicker over the past decade.
An additional institutional-era effect was identified that
could not be explained by any other variables entered into
the risk-factor analysis. The finding that earlier transplanta-
tion date was a risk factor for mortality likely reflects
increasing institutional expertise in many aspects of trans-
plant care, as well as changing methods of immunosuppres-
sion and other scientific advancements, which are generally
incorporated into most institutional transplant protocols. As
seen in Figure 7, the improving institutional-era effect acted
to overcome an increasing risk profile over the decade to
produce the gradual slight overall improvement in survival.
This study also emphasizes the importance of examining
individual institutional performance over time. The often-
used expected versus observed survival at a given institution
is typically based on risk-adjusted expected mortality on the
basis of multi-institutional risk factors and is often reported
by national agencies (eg, the United Network for Organ
Sharing and insurance carriers). The depictions presented
here provide the opportunity to graphically depict changing
institutional factors over time compared with predicted na-
tional outcomes. In many cases it is the ability of the
institution to make progress from within compared with
national standards that is equally as important as their
comparison with national standards at a single point in time.
References
1. Bourge RC, Kirklin JK, Naftel DC, McGiffin DC. Predicting outcome
after cardiac transplantations: lessons from the Cardiac Transplant
Research Database. Curr Opin Cardiol. 1997;12:136-45.
2. Blackstone EH, Naftel DC, Turner ME. The decomposition of time-
varying hazard into phases, each incorporating a separate stream of
concomitant information. J Am Stat Assoc. 1986;81:615-24.
3. McGiffin DC, Naftel DC, Kirklin JK, Morrow WR, Towbin J, Shaddy
R, et al. Predicting outcome after listing for heart transplantation in
children: comparison of Kaplan-Meier and parametric competing risk
analysis. J Heart Lung Transplant. 1997;16:713-22.
4. Kobashigawa JA, Miller L, Runlund D, Mentzer R, Alderman E,
Bourge RC, et al. A randomized controlled trial of mycophenolate
mofetil in heart transplant recipients. Transplantation. 1998;66:507-
15.
5. Meiser BM, Kur F, Uberfuhr P, Reichenspurner H, Kreuzer E,
Reichart B. Modern application for an old compound: 8-methoxypso-
ralen for photochemotherapy after heart transplantation. Transplant
Proc. 1993;25:3307-8.
6. Meiser BM, Kur F, Reichenspurner H, Wagner F, Boos KS, Vielhauer
S, et al. Reduction of the incidence of rejection by adjunct immuno-
suppression with photochemotherapy after heart transplantation.
Transplantation. 1994;57:563-8.
7. Mills RM, Naftel DC, Kirklin JK, VanBakel A, Jaski B, Massin E, et
al. Heart transplant rejection with hemodynamic compromise: a multi-
institutional study of the role of endomyocardial cellular infiltrate.
J Heart Lung Transplant. 1994;16:813-21.
8. Ventura HO, Kirklin JK, Eisen H, Michler R, Clemson B. The com-
bined impact of pretransplant risk factors and rejection frequency and
severity on the prevalence of post transplant coronary vasculopathy.
J Heart Lung Transplant. 1997;16.
9. Kirklin JK, Young JB, McGiffin DC. Heart transplantation. Philadel-
phia: Churchill Livingstone; 2001. p. 615-66.
Appendix 1
CTRD Institutions
1. Abbott Northwestern Hospital
2. Albuquerque Presbyterian Hospital
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3. Bowman Gray School of Medicine
4. Brigham and Women’s Hospital
5. Cleveland Clinic Foundation
6. Downstate Heart Transplant Center
7. Emory University
8. University of Florida, Shands Hospital
9. Henry Ford Hospital
10. Hershey Medical Center
11. Indiana University Hospital
12. Johns Hopkins Hospital
13. Loyola University Medical Center
14. St Luke’s Hospital
15. Medical College of Virginia
16. Massachusetts General Hospital
17. Methodist Hospital of Indiana
18. St Mary’s Hospital, Mayo Clinic
19. Ochsner Clinic Transplant Program
20. Ohio State University, Cardiology
21. Rush Presbyterian-St Luke’s Medical Center
22. Medical University of South Carolina, Charleston
23. Sharp Memorial
24. St Luke’s Episcopal Hospital
25. Sentrara Norfolk Hospital
26. St Louis University
27. Tampa General Hospital
28. Baylor College of Medicine/The Methodist Hospital
29. Temple University School of Medicine
30. Tulane University
31. University of Alabama at Birmingham
32. University of California, Los Angeles
33. University of Cincinnati Medical Center
34. University of Iowa
35. University of Michigan Medical Center
36. University of Minnesota
37. University of Utah Health Sciences Center
38. University of Texas SW Medical Center
39. Hunter Holmes McGuire VA Medical Center
40. Vanderbilt University
41. Washington University Medical Center
42. Yale University School of Medicine
Appendix 2
Variables in the Multivariable Analysis for Death
After Transplantation
Recipient demographic: age, sex, race, height, weight, body
surface area
Donor: age, sex, race, height, weight, body surface area, blood
type, ischemic time, cause of death, diabetes history, degree of
inotropic support (mild [class 1] dopamine, dobutamine, or both
total dose of 5 g  kg1  min1; moderate [class 2]  dopa-
mine, dobutamine, or both total dose of 5-20 g  kg1  min1;
severe [class 3]  dopamine, dobutamine, or both total dose 20
g  kg1 min1) with or without additional pressor agents.
Recipient-donor mismatch variables: race, sex, blood type,
HLA mismatches, weight, body surface area
Clinical variables: United Network for Organ Sharing status at
listing, United Network for Organ Sharing status at transplanta-
tion, justification of status at transplantation (eg, inotropic drugs),
panel-reactive antibody closest to transplantation, cause of heart
failure, diabetes diagnosis, peripheral vascular disease, amioda-
rone use, hyperlipidemia diagnosis, blood type, creatinine level at
listing, creatinine level at transplantation, use of respirator at
transplantation
Hemodynamic variables: right atrial mean pressure, pulmonary
artery pressure, pulmonary capillary wedge pressure, cardiac out-
put, cardiac index, pulmonary vascular resistance
Surgical variables: previous sternotomy (number), type of
transplantation (orthotopic versus heterotopic), date of transplan-
tation
Discussion
Dr Eugene H. Blackstone (Cleveland, Ohio). Dr Kirklin, I
applaud you on a decade of astonishing productivity of your
visionary CTRD. This morning you have presented survival after
cardiac transplantation in 3 novel and only loosely connected
ways. Each is important, interesting, and in need of amplification.
First, you presented competing time-related hazards of various
causes of death. These are reminiscent of those presented 20 years
ago in heart valve replacement. I found risk of death from early
and nonspecific graft failure a particularly interesting pair. Just as
prosthetic valve endocarditis was once split arbitrarily into early
and late prosthetic valve endocarditis, these 2 look like they belong
together in a temporal continuum. However, the most important
information is the marked decline in risk for some modes of death
and relentless continuation of others. Yet calendar date of opera-
tion is terribly nonspecific.
Have you now returned to your database and analyzed those
modes of death to identify specific management strategies and
other factors associated with the declines? What makes other
modes so immutable? Which is influenced by changing patient risk
profile?
Second, you presented the effect of changing risk profiles
across the decade. Your novel way of portraying the effect of
changing risk profile is applicable to every area of cardiothoracic
surgery. Instead of merely showing that patient profile is getting
worse, you have provided a visually appealing and readily under-
stood tool that neatly dissects changes in patient profile from
temporal improvement and then shows the net result. My question
is, how did you do that? I suspect your method is, or should be, an
extension to the time domain of the risk-adjusted cumulative sum
chart introduced by Tom Treasure for monitoring the quality of
surgical programs. Again, have you suppressed the date of oper-
ation to identify treatment factors accounting for improvements?
Finally, you presented monitoring of long-term institutional
quality. You have extended the medical report card concept into
the arena of longitudinal patient care, but might there be more
efficient ways to help institutions gain insight into why their
programs have or have not improved? Perhaps if you used your
risk model as a risk score and then analyzed each institution’s data
for residual risk, the result would be more helpful.
Dr Kirklin, I have read your article avidly, listened to your
presentation eagerly, and now beg for more. Thank you and the
Association for the opportunity to comment on the novel ideas you
and your colleagues have introduced that are broadly applicable
across cardiothoracic surgery.
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Dr Kirklin. Thank you, Dr Blackstone, for your kind remarks.
It is only fitting to pay tribute to Dr Blackstone and his major
contributions in the science of outcomes research in cardiothoracic
surgery, and certainly he has had a profound effect during his years
at UAB in setting the foundation for many of these analyses that
we have applied to cardiac transplantation.
With regard to the issue of a potential continuum between early
graft failure and nonspecific graft failure, certainly that continuum
is present and is true. However, there are situations like that for
which we believe it is useful to categorize separately the event of
early graft failure. There are causes of graft decline that occur later
after transplantation in the setting of normal early function and that
cannot be explained by rejection or allograft vasculopathy and
remain an enigma. Therefore perhaps it is useful to categorize
those separately.
Regarding the issue of date of transplantation as a variable; yes,
it is very nonspecific, yet herein lies one of the difficulties of this
type of analysis. Date of transplantation embodies not only in-
creasing institutional experience and expertise but also new eras of
immunosuppression, changing strategies and modalities of ther-
apy, and so on. Unfortunately, some of these things actually occur
after the transplantaion (ie, the event when we either change
modalities or introduce new immunosuppression). That fact com-
plicates an analysis such as this, which is a pretransplant risk-
factor analysis. We are currently increasing our attention on vari-
ables and events that occur during the first year after
transplantation. We can model predictions of later events from not
only pretransplant variables but also variables that occur during the
first year.
As regards those changes that are immutable, we were disap-
pointed to find that the likelihood of dying from infection, early
graft failure, and malignancy has not decreased during the decade.
We do not believe they are immutable, but the emphasis in all
fields of transplantation has been on developing new immunosup-
pressive drugs and strategies, and therefore it is not surprising that
rejection mortality has decreased. Its relationship to allograft vas-
culopathy is now increasingly clear, and a number of multivari-
able, multi-institutional studies have correlated rejection frequency
and intensity with a higher probability of allograft vasculopathy.
Perhaps that is one reason why total allograft vasculopathy is
decreasing in the face of new immunosuppressive agents and an
increasing emphasis on lipid therapy.
The risk-profile effect was calculated by looking specifically at
each patient within each 6-month interval over the decade. Each of
the patients had his or her cumulative hazard function calculated
on the basis of risk profiles, and the average cumulative hazard was
then translated into a survival curve to generate the predicted
survival on the basis of those risk factors.
Finally, what might we do to help institutions better understand
their report card? This is obviously an important yet sensitive
issue. From an analytic point of view, in general, we apply an
overall multivariable analysis model to an individual institution
and then see what additional risk factors are identifiable in that
institution. In addition, one could do a separate multivariable
analysis if the volume was large enough in a given institution and
compare, if you will, those risk factors overall.
It is important to remember that there are always dangers
because of the fact that a small number of patients at a given
institution might not allow a given risk factor to be unveiled. Also,
if a given institution has a much higher-risk group of donors or
recipients in a way that is not practiced by the overall community
of transplantation, (eg, transplanting patients with a creatinine
level of 3), you might not identify that as an overall risk factor,
even though it might be present at a given institution. Thus it is
important to look individually at factors with an institution before
maligning it too much about less than expected outcome.
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